10:49 AM EDT, 08/01/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday that the US Food and Drug Administration has approved Alhemo (concizumab-mtci) as a once-daily prophylaxis to prevent or reduce the frequency of bleeding in adults and children above 12 years with hemophilia A or B without inhibitors.

The approval is based on the results of a phase 3 trial which showed that Alhemo cut the annualized bleeding rate by 79% in hemophilia B patients and by 86% in hemophilia A patients compared with no prophylaxis, the company said.

The approval offers patients in this population a subcutaneous injection option expanding on the drug's earlier approval in December 2024 for use in patients with hemophilia A or B with inhibitors, Novo Nordisk ( NVO ) said.

Shares of Novo Nordisk ( NVO ) were up 2% in early Friday trading.

Price: 48.10, Change: +1.03, Percent Change: +2.19